End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
14.26 EUR | -1.08% |
|
-4.45% | -40.67% |
Strengths
- The company is one of the most undervalued, with an "enterprise value to sales" ratio at 0.13 for the 2024 fiscal year.
- The company appears to be poorly valued given its net asset value.
- The company has a low valuation given the cash flows generated by its activity.
- This company will be of major interest to investors in search of a high dividend stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- According to forecast, a sluggish sales growth is expected for the next fiscal years.
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- Over the past twelve months, analysts' opinions have been revised negatively.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Sector: Drug Retailers
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-40.67% | 10.44B | - | ||
-45.65% | 8.68B | B | ||
-26.18% | 6.45B | B | ||
-7.49% | 5.98B | C+ | ||
+85.61% | 4.91B | C | ||
-3.80% | 4.57B | D- | ||
+5.73% | 4.49B | B | ||
-26.42% | 4.1B | C | ||
-18.65% | 2.58B | C- | ||
+161.11% | 2.54B | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- WBA Stock
- WBA Stock
- Ratings Walgreens Boots Alliance, Inc.